Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Clinical Hold Placed on Phase II Trial for JCAR015 in Adult ALL

July 9th 2016

The FDA has placed a clinical hold on a phase II study exploring the CD19-targeted CAR-T cell therapy JCAR015 for adult patients with relapsed or refractory B cell acute lymphoblastic leukemia.

EC Grants Brentuximab Vedotin New Indication for Hodgkin Lymphoma

July 6th 2016

The European Commission has approved brentuximab vedotin (Adcetris) for use as a consolidation therapy following autologous stem cell transplantation in patients with CD30-positive Hodgkin lymphoma at risk of relapse or progression.

Ibrutinib Granted Breakthrough Designation for Chronic GVHD

June 30th 2016

The FDA has granted a breakthrough therapy designation to ibrutinib has a potential treatment for patients with chronic graft-versus-host-disease after failure of one or more lines of systemic therapy.

Practical Experience with Iron Chelating Agents

June 28th 2016

Managing Side Effects in Iron Chelation Therapy

June 28th 2016

Deferasirox Formulations in Iron Overload

June 28th 2016

MDS: Iron Chelating Options

June 28th 2016

Deciding When to Treat Excess Iron

June 28th 2016

Improving Quality of Life and Survival in Patients with MDS

June 28th 2016

Monitoring Patients with Iron Overload

June 28th 2016

Excess Iron in MDS

June 28th 2016

Stem Cell Transplantation in Patients with MDS

June 28th 2016

The Effects of Blood Transfusions on Iron Accumulation

June 28th 2016

Classification and Characteristics of MDS

June 28th 2016

Disease Characteristics in MDS

June 28th 2016

Overview and Historical Perspective of MDS

June 28th 2016

Dr. Jorge Sierra on Risk Adapted Therapy in AML

June 23rd 2016

New Criteria and Novel Agents May Help Spur MDS Advances

June 18th 2016

Although knowledge about the underlying biology of myelodysplastic syndromes has expanded rapidly in recent years, translating those findings into advances in the diagnosis and management of patients remains a significant challenge.

Novel T-Cell Engineering Strategy Aims to Reduce GVHD in Lymphoma Transplantations

June 14th 2016

This pilot trial is the first of its type to investigate T cell receptor alpha/beta-depleted and CD19-depleted haploidentical stem cell grafts in relapsed/refractory lymphoma patients.

Inotuzumab Ozogamicin Improves Outcomes in Relapsed/Refractory ALL

June 13th 2016

Inotuzumab ozogamicin demonstrated significantly improved progression-free survival and complete remission rates compared with chemotherapy for patients with relapsed or refractory acute lymphoblastic leukemia.